NASDAQ:ORIC Oric Pharmaceuticals Q1 2025 Earnings Report $11.01 -0.13 (-1.17%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$11.02 +0.01 (+0.05%) As of 07/18/2025 07:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Oric Pharmaceuticals EPS ResultsActual EPS-$0.42Consensus EPS -$0.51Beat/MissBeat by +$0.09One Year Ago EPSN/AOric Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AOric Pharmaceuticals Announcement DetailsQuarterQ1 2025Date5/5/2025TimeBefore Market OpensConference Call DateMonday, May 5, 2025Conference Call Time4:00PM ETUpcoming EarningsOric Pharmaceuticals' Q2 2025 earnings is scheduled for Monday, August 11, 2025, with a conference call scheduled on Sunday, August 10, 2025 at 12:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Oric Pharmaceuticals Earnings HeadlinesOric Pharmaceuticals, Inc. (ORIC) Now Trades Above Golden Cross: Time to Buy?July 15, 2025 | finance.yahoo.comOric Pharmaceuticals, Inc. (ORIC) is a Great Momentum Stock ... - NasdaqJuly 13, 2025 | nasdaq.comMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.July 20 at 2:00 AM | American Alternative (Ad)Ladenburg Thalmann Initiates Coverage of ORIC Pharmaceuticals (ORIC) with Buy RecommendationJuly 9, 2025 | msn.comORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635 (c) (4) - MorningstarJuly 5, 2025 | morningstar.comMORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)July 3, 2025 | globenewswire.comSee More Oric Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Oric Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oric Pharmaceuticals and other key companies, straight to your email. Email Address About Oric PharmaceuticalsOric Pharmaceuticals (NASDAQ:ORIC) is a clinical-stage biotechnology company focused on developing precision medicines for patients with solid tumors that have developed resistance to current therapies. The company’s research efforts center on small molecule agents designed to overcome mechanisms of treatment escape and enhance the durability of existing anticancer regimens. The company’s lead product candidates include ORIC-101, a selective glucocorticoid receptor antagonist being evaluated for patients whose tumors exhibit therapy-induced resistance, and ORIC-533, a potent inhibitor of the ATR kinase that is designed to exploit defects in the DNA damage response pathway. Both programs are advancing through early-stage clinical trials, with Oric providing biomarker-directed patient selection and combination strategies to maximize therapeutic benefit. Founded in 2019 and headquartered in Redwood City, California, Oric Pharmaceuticals has built a streamlined infrastructure to support its clinical development activities across North America and Europe. The company leverages strategic partnerships and external collaborations to accelerate its pipeline, secure trial sites and integrate translational research insights into trial design. Through an experienced leadership team with deep expertise in oncology drug development, Oric aims to deliver innovative treatments to address significant unmet medical needs. By combining targeted mechanisms of action with precision patient selection, the company seeks to improve outcomes for cancer patients who have exhausted standard treatment options.Written by Jeffrey Neal JohnsonView Oric Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Netflix Q2 2025 Earnings: What Investors Need to KnowHow Goldman Sachs Earnings Help You Strategize Your PortfolioCitigroup Earnings Could Signal What’s Next for Markets3 Analysts Set $600 Target Ahead of Microsoft EarningsTesla: 2 Plays Ahead of Next Week's Earnings ReportFastenal Surges After Earnings Beat, Tariff Risks Loom3 Catalysts Converge on Intel Ahead of a Critical Earnings Report Upcoming Earnings NXP Semiconductors (7/21/2025)Verizon Communications (7/21/2025)Comcast (7/22/2025)Intuitive Surgical (7/22/2025)Texas Instruments (7/22/2025)America Movil (7/22/2025)Chubb (7/22/2025)Canadian National Railway (7/22/2025)Capital One Financial (7/22/2025)Danaher (7/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
